Clinical Response to Tricyclic Antidepressants in Functional Bowel Disorders is not Related to Dosage
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: As shown in the per protocol analysis of a recent randomized, controlled trial, when tolerated, Desipramine (DES) is effective over placebo (PLA) in treating moderate-to-severe functional bowel disorders (FBD). Clinical experience suggests that the benefit from tricyclic antidepressants (TCA) in FBD can be achieved at doses lower than those used to treat major depression. Within psychiatry, when using higher dosage of TCAs, plasma levels can be used to adjust daily dosage to optimize a treatment response. However, in FBD, it is not known whether plasma levels at the lower dosage are similarly related to a clinical response. AIM: To determine in treating FBD, whether DES blood levels or dose taken can predict a clinical response. METHODS: As part of a study of 12 wk of antidepressant and psychological treatment in 431 patients with FBD at UNC and U of Toronto, we studied those participants who completed treatment (per protocol analysis) taking DES (N = 97, dose 50-150 mg/day) or pill placebo (PLA) (N = 55 1-3 pills/day). The primary outcome measure was defined as a composite score (Satisfaction with Treatment, McGill Pain Questionnaire, Global Well-being, and IBS-QOL). The composite score was correlated with: (i) DES plasma levels at week 6, and (ii) number of pills taken over the duration of the 12-wk treatment period. In addition, we also compared DES dose with DES plasma levels. RESULTS: There was a modest correlation between mean DES dose at weeks 5 and 6 and DES blood level at week 6 (R = 0.2 p < 0.07). However, there were no significant correlations between the composite score either with DES dose or with DES blood levels. CONCLUSIONS: Detectable blood levels of DES are associated with a clinical response in FBD. However, with dosages up to 150 mg, there is no relationship between total dose or plasma level and the clinical response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
AGA technical review on irritable bowel syndrome.
Drossman, D. A., Camilleri, M., Mayer, E. A., & Whitehead, W. E. (2002) · Gastroenterology · doi:10.1053/gast.2002.37095 · Cited by 1,384
Self-citationPatrick, D. L., Drossman, D. A., Frederick, I. O., Dicesare, J., & Puder, K. L. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1018831127942 · Cited by 761
Self-citationDrossman, D. A., Toner, B. B., Whitehead, W. E., Diamant, N. E., Dalton, C. B., Duncan, S., Emmott, S., Proffitt, V., Akman, D., Frusciante, K., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00669-3 · Cited by 614
Self-citationFurther validation of the IBS-QOL: a disease-specific quality-of-life questionnaire
Drossman, D. A., Patrick, D. L., Whitehead, W. E., Toner, B. B., Diamant, N. E., Hu, Y., Jia, H., & Bangdiwala, S. I. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.01941.x · Cited by 424 · cited 5×
“Rome diagnosis, n = 431 IBS 81.4 Functional constipation 8.5 CFAP 7.41 Characteristic of patients on DES DES (N = 97) (per protocol analysis) VAS Pain (0–100 VAS, 38.3 ± 21.9 mean ± SD/14 days) n = 429 #Stools/day (mean ± 2.3 ± 1.6 SD/14 days) n = 431 Stool consistency (Bristol 4.1 ± 1.3 Stool Form) mean ± SD McGill P…”
MethodInfluentialSelf-citationGORARD, D. A., LIBBY, G. W., & FARTHING, M. J. G. (1994) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1994.tb00273.x · Cited by 211
Gorard, D. A., Libby, G. W., & Farthing, M. J. G. (1995) · Digestive Diseases and Sciences · doi:10.1007/bf02063948 · Cited by 127 · cited 1×
“(i) Alteration of gut motility: TCAs in low doses slow the progress of the MMC in the small bowel and reduce orocecal transit time, while SSRI’s increase orocecal transit time (30, 31); (ii) Alteration of visceral sensitivity: TCAs may also modulate central pain perception by reducing the afferent signals originating…”
Background
Cited by
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
Koloski, N. A., Jones, M., Kalantar, J., Weltman, M., Zaguirre, J., & Talley, N. J. (2012) · Gut · doi:10.1136/gutjnl-2011-300474 · Cited by 611
Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome
Ruepert, L., Quartero, A. O., de Wit, N. J., van der Heijden, G. J., Rubin, G., & Muris, J. W. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003460.pub3 · Cited by 389
Fundamentals of Neurogastroenterology: Basic Science
Vanner, S. J., Greenwood-Van Meerveld, B., Mawe, G. M., Shea-Donohue, T., Verdu, E. F., Wood, J., & Grundy, D. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.018 · Cited by 369
Pain and inflammatory bowel disease.
Bielefeldt, K., Davis, B., & Binion, D. G. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20848 · Cited by 304
Metadata
- Authors
- Halpert, A., Dalton, C. B., Diamant, N. E., Toner, B. B., Hu, Y., Morris, C. B., Bangdiwala, S. I., Whitehead, W. E., & Drossman, D. A.
- Venue
- The American Journal of Gastroenterology
- Published
- 2005-03
- Volume
- 100
- Issue
- 3
- Pages
- 664-671
- ISSN
- 0002-9270 (ISSN-L)
- 1572-0241
- OpenAlex
- W2072359419
- Cited by
- 73
- References
- 7
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Response to Tricyclic Antidepressants in Functional Bowel Disorders is not Related to Dosage. https://app.cochat.ai/papers/10.1111/j.1572-0241.2005.30375.x
- The paper
- Halpert, A., Dalton, C. B., Diamant, N. E., Toner, B. B., Hu, Y., Morris, C. B., Bangdiwala, S. I., Whitehead, W. E., & Drossman, D. A. (2005). Clinical Response to Tricyclic Antidepressants in Functional Bowel Disorders is not Related to Dosage. The American Journal of Gastroenterology. https://doi.org/10.1111/j.1572-0241.2005.30375.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.